Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Purpose: Evaluation of the pharmacodynamics (PD) and pharmacokinetics (PK) of romiplostim alone and in combination with pegfilgrastim in a non-human primate (NHP) model of acute radiation syndrome (ARS).Materials and methods: Male and female rhesus macaques were subjected to Cobalt-60 γ irradiation, at a dose of 550 cGy 24 h prior to subcutaneous administration of either romiplostim alone as a single (2.5 or 5.0 mg/kg on Day 1) or repeat dose (5.0 mg/kg on Days 1 and 8), pegfilgrastim alone as a repeat dose (0.3 µg/kg on Day 1 and 8), or a combination of both agents (romiplostim 5.0 mg/kg on Day 1; pegfilgrastim 0.3 µg/kg on Days 1 and 8). Clinical outcome, hematological parameters and PK were assessed throughout the 45 d study period post-irradiation.Results: Administration of romiplostim, pegfilgrastim or the combination of both resulted in significant improvements in hematological parameters, notably prevention of severe thrombocytopenia, compared with irradiated, vehicle control-treated NHPs. The largest hematologic benefit was observed when romiplostim and pegfilgrastim were administered as a combination therapy with much greater effects on both platelet and neutrophil recovery following irradiation compared to single agents alone.Conclusions: These results indicate that romiplostim alone or in combination with pegfilgrastim is effective at improving hematological parameters in an NHP model of ARS. This study supports further study of romiplostim as a medical countermeasure to improve primary hemostasis and survival in ARS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a randomized, blinded, placebo-controlled study conducted in a rhesus macaque model of TBI-induced ARS, a single subcutaneous injection of Nplate® (5 mg/kg) significantly increased 60-day survival from 32.5% in the control arm to 72.5% in the treatment-arm (p = 0.0002) (Wong et al., 2020).”
From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Wong et al., 2020
In the citing paper
“When combined with a subcutaneous injection of Neulasta on day 1 and day 8 post-TBI, survival was increased to 87.5% (Wong et al., 2020).”
From Medical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space (2022) · cites this paper as Wong et al., 2020
Citations
Cites
Radiobiology for the Radiologist
Fry, R. J. M., & Hall, E. J. (1995) · Radiation Research · doi:10.2307/3579017 · Cited by 1,337
Kuter, D. J., Bussel, J. B., Lyons, R. M., Pullarkat, V., Gernsheimer, T. B., Senecal, F. M., Aledort, L. M., George, J. N., Kessler, C. M., Sanz, M. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60203-2 · Cited by 867
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., Neumann, T. A., & Schwartzberg, L. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.102 · Cited by 482
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Kuter, D. J., Rummel, M., Boccia, R., Macik, B. G., Pabinger, I., Selleslag, D., Rodeghiero, F., Chong, B. H., Wang, X., & Berger, D. P. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002625 · Cited by 427
Panopoulos, A. D., & Watowich, S. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.03.002 · Cited by 394
Sitnicka, E., Lin, N., Priestley, G., Fox, N., Broudy, V., Wolf, N., & Kaushansky, K. (1996) · Blood · doi:10.1182/blood.v87.12.4998.bloodjournal87124998 · Cited by 350
Heil, G., Hoelzer, D., Sanz, M. A., Lechner, K., Liu Yin, J. A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., et al. (1997) · Blood · doi:10.1182/blood.v90.12.4710 · Cited by 332
Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand
WANG, B., NICHOL, J., & SULLIVAN, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.010 · Cited by 295
Ku, H., Yonemura, Y., Kaushansky, K., & Ogawa, M. (1996) · Blood · doi:10.1182/blood.v87.11.4544.bloodjournal87114544 · Cited by 265
Research works printed but not linked: 5
- Neelis KJ, 1997, Exp Hematol, 25, 1084
- NEULASTA®., 2018, (Pegfilgrastrim) [product monograph]
- NEUPOGEN®., 2018, (Filgrastim) [product monograph]
- NPLATE®., 2018, (Romiplostim) [product monograph]
- Wendling F, 1996, Ann Pharm Fr, 54, 177
Cited by
Singh, V. K., & Seed, T. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1702968 · Cited by 125
“The most hematologic advantage in respect to platelet and neutrophil was noted when PEGfilgrastim and Romiplostim were dispensed as a combination therapy.”
BackgroundInfluentialA Review of Romiplostim Mechanism of Action and Clinical Applicability
Bussel, J. B., Soff, G. A., Balduzzi, A., Cooper, N., Lawrence, T. C., & Semple, J. W. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s299591 · Cited by 107
Singh, V. K., & Seed, T. M. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1969054 · Cited by 88
Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry
Obrador, E., Palmer, R. S., Villaescusa, J. I., Gallego, E., Pellicer, B., Estrela, J. M., & Montoro, A. (2022) · Antioxidants · doi:10.3390/antiox11061098 · Cited by 88
A review of the impact on the ecosystem after ionizing irradiation: wildlife population
Cannon, G., & Kiang, J. G. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1793021 · Cited by 48
“2010; Kiang and Olabisi 2019), minipigs (Kiang and Smith, unpublished data) and nonhuman primates (Wong et al. 2020).”
Background
Metadata
- Authors
- Wong, K., Chang, P. Y., Fielden, M., Downey, A. M., Bunin, D., Bakke, J., Gahagen, J., Iyer, L., Doshi, S., Wierzbicki, W., & Authier, S.
- Affiliations
- Citoxlab North America, Laval, Quebec, Canada;
- SRI International (US)
- Amgen (United States) (US)
- Université de Montréal (CA)
- Corresponding author
- Authier, Simon
- Venue
- International Journal of Radiation Biology
- Publisher
- Informa UK Limited
- Published
- 2019-06-21
- Volume
- 96
- Issue
- 1
- Pages
- 155-166
- ISSN
- 0955-3002 (ISSN-L)
- 1362-3095
- OpenAlex
- W2949172829
- Semantic Scholar
- 7d0f33170ee4e759adb3bd340704ee817c343a7b
- Cited by
- 57
- References
- 34
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 10 · 2023: 8 · 2022: 8 · 2021: 7 · 2020: 5 · 2019: 1
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Radiation Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases within the National Institutes of Health
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- romiplostim, pegfilgrastim, radiation sickness, radiation-induced thrombocytopenia, combination therapy, hematopoietic recovery, platelet recovery, nonhuman primate model, cobalt-60 gamma irradiation, medical countermeasures, pharmacodynamics, pharmacokinetics
- MeSH terms
- Filgrastim, Animals, Blood Coagulation, Dose-Response Relationship, Drug, Drug Interactions, Female, Macaca mulatta, Male, Neutropenia, Polyethylene Glycols, Radiation Injuries, Experimental, Receptors, Fc, Recombinant Fusion Proteins, Thrombocytopenia, Thrombopoietin, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates. https://app.cochat.ai/papers/10.1080/09553002.2019.1625488
- The paper
- Wong, K., Chang, P. Y., Fielden, M., Downey, A. M., Bunin, D., Bakke, J., Gahagen, J., Iyer, L., Doshi, S., Wierzbicki, W., & Authier, S. (2020). Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates. International Journal of Radiation Biology. https://doi.org/10.1080/09553002.2019.1625488
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.